StocksMedium•15 October 2026•
1 min read
Ultragenyx to Sell Priority Review Voucher for $203 Million
Key Facts
1Ultragenyx agreed to sell its Priority Review Voucher (PRV) linked to the Fayuvi approval for $203 million.
2This transaction marks the company's second voucher sale within a single week.
Ultragenyx agreed to sell its Priority Review Voucher (PRV) linked to the Fayuvi approval for $203 million. Zacks reported that this transaction marks the company's second voucher sale within a single week.
The sale provides the company with significant non-dilutive funding to strengthen its balance sheet and support ongoing rare-disease research and development programs. The move follows the recent FDA approval of the drug Fayuvi, which triggered the issuance of the voucher.